 |
|
|
|
|
|
|
 |
|
 |
|
|||
 |
|
|||||
 |
 |
 |
 |
|
||
 |
|
|||||
|
||||||
 |
|
|||||
 
|
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
 
|
|
Press Releases ---------------------------------------------------------------- FOR IMMEDIATE RELEASE
IRIS ANNOUNCES FIRST SHIPMENT OF NEW iQ®200 ELITE™ URINE MICROSCOPY ANALYZERS WITH NEW SOFTWARE VERSION 5.0 iQ®200 ELITE™ Is First of Series of New and Enhanced iQ®200 Series Analyzers to Be Shipped as Part of Comprehensive Product Line Expansion CHATSWORTH, Calif., Oct. 9, 2006 — IRIS International, Inc. (NASDAQ: IRIS) a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and clinical reference laboratories worldwide, announced today that its Iris Diagnostics division has shipped the first new iQ®200 ELITE™ Urine Microscopy Analyzers with new Software Version 5.0. The iQ®200 ELITE™ is the first of a series of three new iQ®200 Analyzers to be shipped under the Company's new market segmentation initiative and comprehensive product line expansion, which launched in July at the AACC Expo in Chicago. "The introduction of the new series of iQ®200 urine microscopy analyzers allows the Company to greater penetrate the total available market of 6,500 sites globally, from small hospitals to high volume commercial reference laboratories," stated IRIS President and Chief Executive Officer César García. "The new iQ®200 ELITE™, which performs 70 tests per hour, advances and replaces the current iQ®200 Analyzer and further reinforces Iris Diagnostics as a premier provider of innovative and cost-effective microscopy solutions for medium-sized hospitals. Meanwhile, the new iQ®200 SELECT™, with a throughput of 40 tests per hour targeting smaller facilities, and the new and enhanced iQ®200 SPRINT™, with a throughput of 101 tests per hour serving the needs of high volume hospital and commercial lab markets, have also been released for sale. Taken together, we believe the iQ®200 series of analyzers is the most extensive and most competitive urinalysis product offering in the world." The iQ®200 ELITE™ Analyzer with new Software Version 5.0 contains more than 60 significant improvements in clinical utility and ease of use, including a new category for dysmorphic red blood cells, new quality control features for body fluids analysis and a new touch screen monitor for ease of use. Software Version 5.0 is included in all of the new iQ®200 models and can be used to upgrade iQ®200s already at customer sites. The new software adds three new languages: Chinese, Turkish, and Greek, to better serve those important and growing markets. ABOUT IRIS IRIS International, Inc. (http://www.proiris.com), based in Chatsworth, Calif., is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit (formerly the StatSpin® subsidiary) (www.statspin.com), based in Westwood, Mass., manufactures innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR) (www.adires.com), based near Houston, Texas, is the Company's imaging research and development subsidiary. The IRIS Molecular Diagnostics (IMD) Subsidiary develops innovative ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets. SAFE HARBOR PROVISION This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future commercial revenues, market growth, capital requirements, and new product introductions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: the acceptance by customers of our new iQ®200 product platform, our substantial expansion of international sales and our reliance on key suppliers, the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures, as well as potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and increasing competition from imaging and non-imaging based in-vitro diagnostic products. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors that may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements. |
